Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report)’s share price hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$0.01 and last traded at C$0.01, with a volume of 10000 shares changing hands. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Stock Down 16.7 %
The firm has a market cap of C$1.33 million, a P/E ratio of -1.00 and a beta of 0.05. The firm’s 50-day moving average price is C$0.02 and its 200 day moving average price is C$0.02. The company has a debt-to-equity ratio of 138.88, a current ratio of 0.07 and a quick ratio of 0.46.
Aequus Pharmaceuticals (CVE:AQS – Get Free Report) last issued its earnings results on Thursday, August 29th. The company reported C($0.01) EPS for the quarter. The firm had revenue of C$0.16 million during the quarter. On average, equities research analysts expect that Aequus Pharmaceuticals Inc. will post -0.1 earnings per share for the current fiscal year.
About Aequus Pharmaceuticals
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
Featured Articles
- Five stocks we like better than Aequus Pharmaceuticals
- What does consumer price index measure?
- Why Lennar Stock Could Be the Best Play in the Housing Market
- 3 Monster Growth Stocks to Buy Now
- 2 Energy Stocks Fueling the AI Datacenter Boom
- Why Invest in 5G? How to Invest in 5G Stocks
- Will Marinus Pharmaceuticals Be the Next Big Winner in Biotech?
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
